Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01376011 · ClinicalTrials.gov registry record · Early Phase 1

Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement

A Early Phase 1 study of Stroke and Problem of Aging, sponsored by Brigham and Women's Hospital.

Completed
Registry status
Early Phase 1
Development phase
106
Enrollment target
1
Study location

NCT01376011: Completed Early Phase 1 study of Stroke and Problem of Aging, sponsored by Brigham and Women's Hospital.

NCT01376011 is a Early Phase 1 study of Stroke and Problem of Aging that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 106 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01376011, a Early Phase 1 study of Stroke and Problem of Aging, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
Early Phase 1
Development phase
106 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to find out if quercetin can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

Primary Outcome

Baseline and 6 month blood samples will be analyzed for levels of HIF-1, VEGF, EPO, and NOS

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT quercetin/placebo

Study Locations (1)

Massachusetts

  • Brigham and Women's Hospital - Boston

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2009-06
Est. Completion 2014-12
Phase Early Phase 1
Brigham and Women's Hospital

937 total trials

What the finished NCT01376011 record still lists

NCT01376011 is an interventional study that assigns participants to a tested intervention. The registered 106 participants enrollment target is mid-sized for trials with a published cap, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which quercetin/placebo is the first listed.

NCT01376011 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01376011 about?

NCT01376011 is a clinical study titled "Modulation of Cerebral Blood Flow Using Quercetin, a Nutritional Supplement". The purpose of this study is to find out if quercetin can increase blood levels of hypoxia-inducible transcription factor 1 (HIF-1 protein) and to see if there is a corresponding increase in blood flow to the brain.

What is the current status of trial NCT01376011?

This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 106 participants. The study started on 2009-06. Estimated completion is 2014-12.

What conditions does trial NCT01376011 study?

This clinical trial studies the following conditions: Stroke, Problem of Aging.

What interventions are being tested in trial NCT01376011?

The interventions under investigation include: quercetin/placebo (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01376011?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01376011 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stroke

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01376011's enrollment target sits among peer trials

106 131st of 454 higher than 324 of 454 other Stroke trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03181048 · 106 participants · NA

    Clinical Trial of Concomitant Hip Arthroscopy During PAO

  • NCT04682158 · 106 participants · Phase 2

    Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

  • NCT04724018 · 106 participants · Phase 1

    Sacituzumab Govitecan Plus EV in Metastatic UC

  • NCT04798274 · 106 participants · NA

    Role of GABAergic Transmission in Auditory Processing in Autism Spectrum Disorder

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01376011, the US trial registry maintained by the National Library of Medicine. NCT01376011 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.